-
公开(公告)号:US20220259226A1
公开(公告)日:2022-08-18
申请号:US17660355
申请日:2022-04-22
发明人: Wilfried Braje , George Doherty , Katja Jantos , Cheng Ji , Andrew Judd , Aaron Kunzer , Anthony Mastracchio , Xiaohong Song , Andrew Souers , Gerard Sullivan , Zhi-Fu Tao , Chunqiu Lai , Jesse Teske , Michael Wendt , Patrick Brady , Xilu Wang , Thomas Penning , Yujia Dai , Jane Gong , Roberto Risi , Yiyun Yu , Guidong Zhu
IPC分类号: C07D498/18 , A61P35/00 , C07D519/00 , C07D495/18 , C07D495/16 , A61K31/519 , C07D491/16 , C07D498/16
摘要: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
-
公开(公告)号:US20200010480A1
公开(公告)日:2020-01-09
申请号:US16575114
申请日:2019-09-18
发明人: Patrick B. Brady , Wilfried Braje , Yujia Dai , George A. Doherty , Jane Gong , Katja Jantos , Cheng Ji , Andrew S. Judd , Aaron R. Kunzer , Chunqiu Lai , Anthony Mastracchio , Roberto M. Risi , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Jesse A. Teske , Xilu Wang , Michael D. Wendt , Yiyun Yu , Guidong Zhu , Thomas D. Penning
IPC分类号: C07D498/18 , A61P35/00 , C07D519/00 , C07D495/18 , C07D495/16
摘要: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
-
公开(公告)号:US20190055264A1
公开(公告)日:2019-02-21
申请号:US15998688
申请日:2018-08-15
发明人: Patrick B. Brady , Wilfried Braje , Yujia Dai , George A. Doherty , Jane Gong , Katja Jantos , Cheng Ji , Andrew S. Judd , Aaron R. Kunzer , Chunqiu Lai , Anthony Mastracchio , Roberto M. Risi , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Jesse A. Teske , Xilu Wang , Michael D. Wendt , Yiyun Yu , Guidong Zhu , Thomas D. Penning
IPC分类号: C07D498/18 , C07D495/18 , C07D519/00 , A61P35/00
摘要: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
-
公开(公告)号:US20180071262A1
公开(公告)日:2018-03-15
申请号:US15727220
申请日:2017-10-06
申请人: AbbVie Inc.
发明人: Edward A. Kesicki , Arthur F. Kluge , Michael A. Patane , John H. Van Drie, JR. , Ce Wang , Maricel Torrent , Michael L. Curtin , Todd M. Hansen , Rick F. Clark , Robin R. Frey , Zhiqin Ji , Yujia Dai , William J. McClellan , Jane Gong , Gui-dong G. Zhu , Anthony Mastracchio , Michael R. Michaelides , Thomas D. Penning , Chunqiu C. Lai
IPC分类号: A61K31/4184 , C07D498/10 , C07D403/06 , C07D493/10 , C07D491/107 , C07D263/52 , C07D417/12 , C07D417/04 , C07D413/12 , C07D413/04 , C07D409/12 , C07D407/12 , C07D401/12 , C07D235/02 , C07D413/14 , C07D403/12 , C07D409/06 , C07D405/06 , A61K31/423 , A61K31/4439 , C07D401/06 , C07D495/10
CPC分类号: A61K31/4184 , A61K31/423 , A61K31/4439 , C07D235/02 , C07D263/52 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/06 , C07D407/12 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D491/107 , C07D493/10 , C07D495/10 , C07D498/10
摘要: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
-
公开(公告)号:US20160235716A1
公开(公告)日:2016-08-18
申请号:US14857419
申请日:2015-09-17
申请人: ABBVIE INC.
发明人: Edward A. Kesicki , Arthur F. Kluge , Michael A. Patane , John H. Van Drie, JR. , Ce Wang , Maricel Torrent , Michael L. Curtin , Todd M. Hansen , Rick F. Clark , Robin R. Frey , Zhiqin Ji , Yujia Dai , William J. McClellan , Jane Gong , Gui-dong G. Zhu , Anthony Mastracchio , Michael R. Michaelides , Thomas D. Penning , Chunqiu C. Lai
IPC分类号: A61K31/4184 , C07D403/06 , C07D405/06 , A61K31/423 , C07D401/06 , A61K31/4439 , C07D263/52 , C07D235/02 , C07D409/06
CPC分类号: A61K31/4184 , A61K31/423 , A61K31/4439 , C07D235/02 , C07D263/52 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/06 , C07D407/12 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D491/107 , C07D493/10 , C07D495/10 , C07D498/10
摘要: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1- - - -Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
摘要翻译: 具有式(IX)结构的化合物或其立体异构体,互变异构体或其药学上可接受的盐,其中R1,R2a,R2b,R3a,R3b,R4a,R4b,Q1- - -Q2,R6,R7,A,B ,W,x和y如本文所定义并提供。 还提供了包含这些化合物的药物组合物和通过施用这些化合物治疗各种HAT相关病症或疾病(包括癌症)的方法。
-
6.
公开(公告)号:US20140296220A1
公开(公告)日:2014-10-02
申请号:US14307680
申请日:2014-06-18
申请人: AbbVie Inc.
发明人: Gui-Dong Zhu , Jane Gong , Andrew S. Judd , Virajkumar B. Ghandi , Alexander R. Shoemaker , Thomas D. Penning , Michael R. Michaelides , Chunqiu Lai , Keith W. Woods
IPC分类号: C07D487/04
CPC分类号: C07D487/04
摘要: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein B, R1, R2, R4, and m are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.
摘要翻译: 本发明涉及式(I)化合物或其药学上可接受的盐,其中B,R 1,R 2,R 4和m在说明书中定义。 本发明还涉及含有所述化合物的组合物,其可用于抑制诸如wee-1的激酶和治疗诸如癌症的疾病的方法。
-
公开(公告)号:US20180193315A1
公开(公告)日:2018-07-12
申请号:US15907597
申请日:2018-02-28
申请人: AbbVie Inc.
发明人: Edward A. Kesicki , Arthur F. Kluge , Michael A. Patane , John H. Van Drie, JR. , Ce Wang , Maricel Torrent , Michael L. Curtin , Todd M. Hansen , Rick F. Clark , Robin R. Frey , Zhiqin Ji , Yujia Dai , William J. McClellan , Jane Gong , Gui-dong G. Zhu , Anthony Mastracchio , Michael R. Michaelides , Thomas D. Penning , Chunqiu C. Lai
IPC分类号: A61K31/4184 , C07D403/06 , C07D498/10 , A61K31/4439 , A61K31/423 , C07D405/06 , C07D409/06 , C07D403/12 , C07D413/14 , C07D235/02 , C07D401/12 , C07D407/12 , C07D409/12 , C07D413/04 , C07D413/12 , C07D417/04 , C07D417/12 , C07D263/52 , C07D491/107 , C07D493/10 , C07D495/10 , C07D401/06
CPC分类号: A61K31/4184 , A61K31/423 , A61K31/4439 , C07D235/02 , C07D263/52 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/06 , C07D407/12 , C07D409/06 , C07D409/12 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D491/107 , C07D493/10 , C07D495/10 , C07D498/10
摘要: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1-Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
-
公开(公告)号:US09328112B2
公开(公告)日:2016-05-03
申请号:US14568153
申请日:2014-12-12
申请人: AbbVie Inc.
发明人: Robin Frey , Jane Gong , Zhiqin Ji , Chunqiu Lai , Thomas Penning , Xiaohong Song , Andrew Souers , Yunsong Tong , Gui-Dong Zhu
IPC分类号: A61K31/437 , A61K31/55 , C07D471/16 , C07D498/16 , C07D519/00
CPC分类号: C07D471/16 , A61K31/437 , A61K31/55 , C07D498/16 , C07D519/00
摘要: Disclosed are compounds of Formula (Ia), and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3A, R3B, and R4 are as described herein. The compounds may be used as agents in the treatment of diseases, including cancer. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (Ia).
摘要翻译: 公开了式(Ia)化合物及其药学上可接受的盐,其中X,Y,R 1,R 2,R 3A,R 3B和R 4如本文所述。 这些化合物可以用作治疗包括癌症在内的疾病的药剂。 还公开了包含一种或多种式(Ia)化合物的药物组合物。
-
公开(公告)号:US20230312601A1
公开(公告)日:2023-10-05
申请号:US18192810
申请日:2023-03-30
申请人: AbbVie Inc.
发明人: Daniel Cohen , Jane Gong , Tarun Jain , Puneet Kumar , Dachun Liu , Anthony Mastracchio , Mark Mills , Andrew William Phillips , John K. Pratt , Sreenivas Punna , Jennifer Ann Stockwell , Le Wang , Yiyun Yu
IPC分类号: C07D513/04 , A61P35/00
CPC分类号: C07D513/04 , A61P35/00
摘要: The present disclosure provides for compounds of the general Formula (I)
wherein R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and Ring A have any of the values defined in the specification, and pharmaceutically acceptable salts thereof.-
10.
公开(公告)号:US09051327B2
公开(公告)日:2015-06-09
申请号:US14307680
申请日:2014-06-18
申请人: AbbVie Inc.
发明人: Gui-Dong Zhu , Jane Gong , Andrew S. Judd , Virajkumar B. Gandhi , Alexander R. Shoemaker , Thomas D. Penning , Michael R. Michaelides , Chunqiu Lai , Keith W. Woods
IPC分类号: A01N43/90 , A61K31/519 , C07D487/02 , C07D487/04
CPC分类号: C07D487/04
摘要: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein B, R1, R2, R4, and m are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.
摘要翻译: 本发明涉及式(I)化合物或其药学上可接受的盐,其中B,R 1,R 2,R 4和m在说明书中定义。 本发明还涉及含有所述化合物的组合物,其可用于抑制诸如wee-1的激酶和治疗诸如癌症的疾病的方法。
-
-
-
-
-
-
-
-
-